Adds share movement in paragraph 2, disease background in paragraph 3, trial details in paragraphs 4-5
Jan 15 (Reuters) - Keros Therapeutics KROS.O said on Wednesday it would voluntarily halt testing of its experimental blood pressure treatment due to safety concerns during a mid-stage trial.
Its shares fell 8% to $11.52 in premarket trading.
The company was testing the therapy, cibotercept, in patients with pulmonary arterial hypertension — a rare, progressive lung disease that causes high blood pressure in the pulmonary arteries.
Keros said it observed excess fluid build up around the heart in patients. It is terminating the trial early and will monitor patients who were part of the study.
The company expects to present clinical data from the trial in the second quarter of 2025.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.